Showing 4721-4730 of 8697 results for "".
- NPF Task Force Issues New Guidance on COVID-19 Vaccine Boosters for PsO Patientshttps://practicaldermatology.com/news/npf-task-force-issues-new-guidance-on-covid-19-vaccine-boosters-for-pso-patients/2460911/The Centers for Disease Control and Prevention (CDC) recently released new information on COVID-19 vaccines for moderately to severely immunocompromised people. Since these individuals may be especially vulnerable to COVID-19, due to their increased
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- Public Citizen to FDA: Pull Propecia from the Markethttps://practicaldermatology.com/news/public-citizen-to-fda-pull-propecia-from-the-market/2460908/Public Citizen today filed a lawsuit on behalf of the Post-Finasteride Syndrome Foundation (PFSF) against the U.S. Food and Drug Administration (FDA) fo
- Study: UV Exposure Produces Epigenetic Changes in the Epidermis to Induce Skin Pigmentationhttps://practicaldermatology.com/news/study-uv-exposure-produces-epigenetic-changes-in-the-epidermis-to-induce-skin-pigmentation/2460905/Exposure to the sun's ultraviolet (UV) rays produces epigenetic changes in the epidermis to induce skin pigmentation, a new study shows. UV exposure causes DNA damage in epidermal cells and is a leading cause of skin cancers. To protect from the damaging effects of UV exposure, epid
- FDA: Omeza's Collagen Matrix Cleared for Marketinghttps://practicaldermatology.com/news/fda-omezas-collagen-matrix-cleared-for-marketing/2460904/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Omeza Collagen Matrix for chronic wound care. Omeza Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin pr
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- Business News: Crown Labs to Acquire StriVectinhttps://practicaldermatology.com/news/business-news-crown-labs-acquire-strivectin/2460897/Crown Laboratories is slated to acquire StriVectin from the private equity firm L Catterton. The transaction is expected to close by mid-September and is subject to regulatory approvals and other customary closing conditions. Terms of the transaction were not disclosed.
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- European Commission Approves UCB's BIMZELX for Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/european-commission-approves-ucbs-bimzelx-for-adults-with-moderate-to-severe-plaque-psoriasis/2460895/The European Commission (EC) has granted marketing authorization for UCB's bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab is the first approved treatment in the European Union (EU) for moderate